Share Name Share Symbol Market Type Share ISIN Share Description
Motif Bio Plc LSE:MTFB London Ordinary Share GB00BVVT4H71 ORD 0.01P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 0.16275 0.13 0.195 0.00 0.00 - 1,325,972 09:23:46
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -11.0 -3.9 - 1

Motif Bio Share Discussion Threads

Showing 4551 to 4575 of 4575 messages
Chat Pages: 183  182  181  180  179  178  177  176  175  174  173  172  Older
DateSubjectAuthorDiscuss
19/2/2020
12:53
Sells and buys today are nowhere near "indicative" IMO.
small crow
18/2/2020
14:35
Lets hope it return to double.figures...
acuransx
18/2/2020
14:00
I think you're right !
oldbronze
18/2/2020
13:58
Nice price up !++++
bygdennis
14/2/2020
10:35
Kat on the up !
oldbronze
10/2/2020
13:48
Compared to what oldbronze?
philoosh
10/2/2020
12:40
looking a bit better now !
oldbronze
09/2/2020
18:51
Hopefully hercules cap does support them and goes to 20p thats a big jump from where it is now...
acuransx
06/2/2020
13:35
Ok thanks for taking the time to give your views- much appreciated.
smcl
06/2/2020
12:56
The truth is that this share has moved in mysterious ways for three years or so but, if you believe in divine benevolence yes, there might be value. Imagine it back at 40p and one could get quite excited but that may well take a miracle.
small crow
06/2/2020
12:46
Hi- anybody have any positives to say on this. Been a bit of a disaster but not rejected as a therapy just needs somebody willing with deeper pockets to take on! I know not great but is there value from this price?
smcl
04/2/2020
16:59
Zen. Sorry, but you're being bamboozled by their marketing pitch. "Iclaprim has a different chemical structure and mechanism of action relative to other classes of antibacterial compounds (e.g., fluoroquinolones, aminoglycosides, macrolides, beta-lactams, glycopeptides, tetracyclines and oxazolidinones)." This is quite true but completely misses the point that it's an analogue of trimethoprim. It's like saying that a pig is quite different from a sheep, goat, cow etc etc, but omitting the fact that it closely resembles a wild boar. For the structures see: https://www.researchgate.net/figure/Chemical-structures-of-iclaprim-a-and-trimethoprim-b_fig1_24002671 The similarity should be obvious.
vulgaris
04/2/2020
16:11
I'm not sure you understand any of what you just pasted. Vulgaris has given you a concise summary. Whatever saves the share price it won't be Coronavirus.
small crow
04/2/2020
16:06
Cont..this "precision medicine approach" is consistent with antibiotic stewardship principles which, among other things, seek to reduce the inappropriate use of broad-spectrum products to avoid antimicrobial resistance and to lessen the impact on the microbiome of the patient.Iclaprim has a different and underutilized mechanism of action compared to most other antibiotics. Motif Bio is seeking approval of iclaprim from the U.S. Food & Drug Administration (FDA) for the treatment of acute bacterial skin and skin structure infections (ABSSSI). To date, iclaprim has been studied in nearly 1,500 patients and healthy volunteers. Clinical and microbiological data indicate that iclaprim has a targeted Gram-positive spectrum of activity and low propensity for resistance development. In the REVIVE clinical studies, iclaprim was administered intravenously at a fixed dose with no dosage adjustment required in patients with renal impairment or in obese patients. The iclaprim fixed dose may, if approved, help reduce the resources required in hospitals since dosage adjustment by health care professionals is avoided, therapeutic drug monitoring is not needed, and overall hospital treatment costs may be lower, especially in patients with renal impairment. Many standard of care Gram-positive antibiotics are not suitable for hospitalized ABSSSI patients with renal impairment due to efficacy and/or safety issues.
zen12
04/2/2020
16:04
Iclaprim is a targeted Gram-positive1 antibiotic with activity against methicillin-resistant Staphylococcus aureus (MRSA). Iclaprim works in a different way than most other antibiotics and rapidly kills bacteria in vitro.KEY INFORMATIONTwo Phase 3 trials in ABSSSI completed; seeking FDA approval for the treatment of ABSSSI.Iclaprim, if approved, may have the potential to provide avoidance of costs related to vancomycin-associated acute kidney Injury (VA-AKI) (est. ~$17,000 per patient) in hospitalized ABSSSI patients at risk or with existing moderate to severe renal impairment. It is estimated that up to 8-10% of hospitalized ABSSSI patients have moderate to severe renal impairment or risk factors for VA-AKI. Iclaprim has a different chemical structure and mechanism of action relative to other classes of antibacterial compounds (e.g., fluoroquinolones, aminoglycosides, macrolides, beta-lactams, glycopeptides, tetracyclines and oxazolidinones).Iclaprim is a next-generation diaminopyrimidine and belongs to the class of selective dihydrofolate reductase (DHFR) inhibitors. Iclaprim has a low propensity for resistance development and is rapidly bactericidal in vitro.Targeted spectrum of activity against Gram-positive bacteria, including MRSA; aligned with antibiotic stewardship principles.Studied in nearly 1,500 patients and healthy volunteers.Administered intravenously at a fixed dose with no dosage adjustment required in renally impaired or obese patients. Iclaprim fixed dose may, if approved, help reduce the resources required in hospitals since dosage adjustment by health care professionals is avoided, no therapeutic drug monitoring is needed, and overall hospital treatment costs may be lower, especially in patients with renal impairment.Concentrates in the skin and lung following intravenous administration; less than 2% excreted unchanged through kidneys; no clinically relevant drug-drug interactions.Commercial potential in at least three hospitalized patient segments with serious MRSA infections and unmet medical needs – ABSSSI (including patients at risk of VA-AKI), hospital-acquired bacterial pneumonia (HABP), including ventilator-associated bacterial pneumonia (VABP), and Staphylococcus aureus lung infections in patients with cystic fibrosis.Qualified Infectious Disease Product (QIDP) designation granted by FDA, and, if approved as a New Chemical Entity, will be eligible for 10 years of market exclusivity in the U.S. upon approval.Two U.S. method of use patents that will expire in 2037.OVERVIEWIclaprim is a novel investigational antibiotic with a targeted Gram-positive spectrum of activity. In contrast to commonly used broad-spectrum antibiotics, this "precision medicine
zen12
04/2/2020
15:56
Zen, iclaprim isn't years ahead. It's a twice-rejected derivative of trimethoprim, an antibiotic that has been around since the 70s. It overcomes some trimethoprim resistance in gram-postive bacteria (notably S. aureus) and is inherently more active than trimethoprim vs. pneumococci, at least in the lab (we lack trials in the lung). It lacks activity against trimethoprim-resistant gram-negatives. Even if Wuhan CoV patients prove prone to getting subsequent pneumonias with S. aureus and pneumococci (& some think these bugs caused a lot of secondary infections & mortality in the 1918 flu pandemic) there are plenty of already licensed antibiotics active against them.
vulgaris
04/2/2020
15:11
Zen mate, you nothing about this. Yeah. True.
small crow
04/2/2020
15:07
Yeah but it's way advanced than other drugs being developed since the C-virus outbreak. So Iclaprim is years ahead and way advanced than these. You never know what's round the corner, and what drug can work on this..could end up requiring a mixture of anti-viral and antibiotic drugs...
zen12
04/2/2020
14:33
Secondary bacterial infection may follow viral infection, but scant evidence that this is a significant issue with Wuhan coronavirus (in a recent lancet publication only 1/99 cases had bacterial co-infection and only 6/99 had raised procalcitonin--- which is reasonable pointer to bacterial co-involvement). And absolutely no reason to suppose that iclaprim would either be ready or have any advantage over other antibiotics even if such pneumonias do occur. It hasn't even had proper trials in the lung.
vulgaris
04/2/2020
14:00
Meaning what does this virus lead to?
zen12
04/2/2020
13:40
..."as with the case here"??? Don't know what you mean. It's the inflammation associated with the viral infection that stops oxygenation of the blood in ARDS. Nothing to do with bacteria.
small crow
04/2/2020
11:46
Not quite, if the virus then becomes an infection as with the case here, then how do you think this is treated? Antibiotics.
zen12
03/2/2020
22:58
Coronavirus is a virus. Antibiotics have no effect on viruses .... for the 1000th time.
small crow
03/2/2020
19:36
You reckon this will ever recover...those at 40p damn...what the hell..i wonder if coronavirus anecdote may be of interest for them..if they take interest surely share price will.boom up
acuransx
03/2/2020
13:52
It's blue now !
oldbronze
Chat Pages: 183  182  181  180  179  178  177  176  175  174  173  172  Older
Your Recent History
LSE
MTFB
Motif Bio
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200224 10:02:00